[go: up one dir, main page]

WO2003038113A3 - Methodes et compositions destinees au traitement et au diagnostic de troubles lies a la proliferation cellulaire au moyen de 25943 - Google Patents

Methodes et compositions destinees au traitement et au diagnostic de troubles lies a la proliferation cellulaire au moyen de 25943 Download PDF

Info

Publication number
WO2003038113A3
WO2003038113A3 PCT/US2002/034730 US0234730W WO03038113A3 WO 2003038113 A3 WO2003038113 A3 WO 2003038113A3 US 0234730 W US0234730 W US 0234730W WO 03038113 A3 WO03038113 A3 WO 03038113A3
Authority
WO
WIPO (PCT)
Prior art keywords
cellular proliferation
methods
diagnosis
compositions
treatment
Prior art date
Application number
PCT/US2002/034730
Other languages
English (en)
Other versions
WO2003038113A2 (fr
Inventor
Mark Williamson
Laura A Rudolph-Owen
Original Assignee
Millennium Pharm Inc
Mark Williamson
Laura A Rudolph-Owen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Mark Williamson, Laura A Rudolph-Owen filed Critical Millennium Pharm Inc
Priority to JP2003540378A priority Critical patent/JP2005507669A/ja
Priority to AU2002350053A priority patent/AU2002350053A1/en
Priority to EP02786586A priority patent/EP1440165A4/fr
Publication of WO2003038113A2 publication Critical patent/WO2003038113A2/fr
Publication of WO2003038113A3 publication Critical patent/WO2003038113A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des méthodes et des compositions destinées au traitement et au diagnostic de troubles liés à la prolifération cellulaire, notamment mais sans caractère restrictif, le cancer du sein, le cancer des ovaires, le cancer des poumons et le cancer du côlon. L'invention concerne également des méthodes d'identification d'un composé capable de traiter des troubles liés à la prolifération cellulaire ou de moduler la prolifération cellulaire. L'invention concerne en outre, un procédé de modulation de la prolifération cellulaire, par exemple, une modulation de la prolifération cellulaire chez un sujet. De plus, l'invention concerne une méthode de traitement d'un sujet souffrant d'un trouble lié à la prolifération cellulaire et caractérisé par une activité polypeptidique 25943 aberrante ou une expression aberrante d'acides nucléiques 25943.
PCT/US2002/034730 2001-10-31 2002-10-29 Methodes et compositions destinees au traitement et au diagnostic de troubles lies a la proliferation cellulaire au moyen de 25943 WO2003038113A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003540378A JP2005507669A (ja) 2001-10-31 2002-10-29 ２５９４３を用いる細胞増殖障害の処置および診断のための方法および組成物
AU2002350053A AU2002350053A1 (en) 2001-10-31 2002-10-29 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
EP02786586A EP1440165A4 (fr) 2001-10-31 2002-10-29 Methodes et compositions destinees au traitement et au diagnostic de troubles lies a la proliferation cellulaire au moyen de 25943

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33500401P 2001-10-31 2001-10-31
US60/335,004 2001-10-31

Publications (2)

Publication Number Publication Date
WO2003038113A2 WO2003038113A2 (fr) 2003-05-08
WO2003038113A3 true WO2003038113A3 (fr) 2004-01-29

Family

ID=23309817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034730 WO2003038113A2 (fr) 2001-10-31 2002-10-29 Methodes et compositions destinees au traitement et au diagnostic de troubles lies a la proliferation cellulaire au moyen de 25943

Country Status (5)

Country Link
US (2) US20030124593A1 (fr)
EP (1) EP1440165A4 (fr)
JP (1) JP2005507669A (fr)
AU (1) AU2002350053A1 (fr)
WO (1) WO2003038113A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20070455A0 (fi) * 2007-06-08 2007-06-08 Reagena Ltd Oy Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
BR102018001033A2 (pt) * 2018-01-18 2019-07-30 Fundação Oswaldo Cruz Polipeptídeo com atividade asparaginase, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, métodos para produzir um polipeptídeo com atividade asparaginase e para prevenir ou tratar câncer, e, uso de um polipeptídeo.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020038014A1 (en) * 2000-03-24 2002-03-28 Meyers Rachel A. 26443 and 46837, novel human asparaginase family members and uses therefor
US20020173639A1 (en) * 2001-03-26 2002-11-21 Friddle Carl Johan Novel human asparaginases and polynucleotides encoding the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569662B1 (en) * 2000-01-21 2003-05-27 Hyseq, Inc. Nucleic acids and polypeptides
CA2402563A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
US20030165831A1 (en) * 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020038014A1 (en) * 2000-03-24 2002-03-28 Meyers Rachel A. 26443 and 46837, novel human asparaginase family members and uses therefor
US20020173639A1 (en) * 2001-03-26 2002-11-21 Friddle Carl Johan Novel human asparaginases and polynucleotides encoding the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1440165A4 *

Also Published As

Publication number Publication date
WO2003038113A2 (fr) 2003-05-08
AU2002350053A1 (en) 2003-05-12
JP2005507669A (ja) 2005-03-24
EP1440165A2 (fr) 2004-07-28
EP1440165A4 (fr) 2005-03-30
US20030124593A1 (en) 2003-07-03
US20060088880A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
IL147271A (en) Isolated peptide ligands that bind to her2
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
WO2005023202A3 (fr) Activation directe de la kinase activee par l'amp reposant sur l'utilisation de la kinase lkb1, suppresseur de tumeurs
WO2003013534A3 (fr) Moyens et procedes de traitement ameliore du cancer sur la base de cyp3a5
WO2003079020A3 (fr) Methodes et compositions d'identification, d'evaluation, et de traitement du cancer du poumon a petites cellules
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
WO2003000012A3 (fr) Compositions, necessaires et methodes destines a l'identification, a l'evaluation, a la prevention et au traitement des cancers du sein et de l'ovaire
WO2002067868A3 (fr) Procede destines au traitement de troubles metaboliques, y compris l'obesite et le diabete
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
WO2003045230A3 (fr) Compositions et procedes contre le cancer
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2004058158A3 (fr) Traitement du cancer metastatique avec la sous-unite de la toxine de shiga
WO2004055513A3 (fr) Utilisation d'antagonistes de cd137 pour le traitement de tumeurs
WO2002081745A3 (fr) Genes impliques dans l'osteogenese et procedes d'utilisation associes
WO2003057146A3 (fr) Compositions et procedes concernant le cancer
WO2004076614A3 (fr) Sequences d'acide nucleique humaines issues de carcinomes de la prostate
WO2003037257A3 (fr) Methodes et compositions servant au diagnostic et au traitement de troubles de la proliferation cellulaire impliquant le 20750
WO2003053224A3 (fr) Nouvelles compositions et methodes contre le cancer
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2003038113A3 (fr) Methodes et compositions destinees au traitement et au diagnostic de troubles lies a la proliferation cellulaire au moyen de 25943
WO2003035837A3 (fr) Nouvelles compositions et procedes relatifs au cancer
WO2003087840A3 (fr) Proteine intervenant dans le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002786586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003540378

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002786586

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002786586

Country of ref document: EP